LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis. The Company will present a five-year analysis of the THN-3 randomized control trial (RCT), which studied the use of its aura6000 System for the treatment of moderate to severe obstructive sleep apnea (OSA). LivaNova will also deliver an oral presentation and feature a scientific poster to support a deeper understanding of the use of proximal hypoglossal nerve stimulation (p-HGNS) for OSA, including 12-month, top-line data from its follow-on RCT, OSPREY.

“Nearly 2 million patients with moderate to severe OSA have failed first-line therapies. These patients have a high need for an effective solution, and that is the problem LivaNova is working to solve,” said Ahmet Tezel, Ph.D., Chief Innovation Officer of LivaNova. “At ISSS, we will have two oral presentations and a poster showcasing the continued durability and retention of benefits we are seeing when p-HGNS therapy is used to treat OSA. We’re eager to share these positive outcomes and continue our efforts to bring this innovative treatment to market.”

The oral and scientific poster presentations feature the research of independent investigators:

Thurs., Oct. 9, from 11 a.m.-12 p.m. EDT during Research Abstracts

• Phenotypical Trajectories of Subjects Receiving Proximal Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea: A 5-Year Analysis of the THN-3 Randomized, Controlled Trial – Oral presentation by Alan Schwartz, M.D., Adjunct Professor of Otorhinolaryngology, Perelman School of Medicine at the University of Pennsylvania, from 11:00-11:08 a.m. EDT.

Fri. Oct. 10, from 1-2 p.m. EDT during Research Abstracts

• Proximal Hypoglossal Nerve Stimulation Improves Sleep-Disordered Breathing, Oxygenation, and Quality of Life at One Year in Moderate to Severe Obstructive Sleep Apnea in the OSPREY Trial – Presented by Ofer Jacobowitz, M.D., Ph.D., Otolaryngologist at ENT and Allergy Associates and Clinical Professor of Otolaryngology, Zucker School of Medicine at Hofstra University/Northwell Health, from 1:48-1:56 p.m. EDT.

Fri., Oct. 10, from 5-7 p.m. EDT during the ISSS Welcome Reception